These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37334561)

  • 1. Aprocitentan: A new development of resistant hypertension.
    Yao Y; Fan B; Yang B; Jia Z; Li B
    J Clin Hypertens (Greenwich); 2023 Jul; 25(7):587-590. PubMed ID: 37334561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aprocitentan: First Approval.
    Dhillon S
    Drugs; 2024 Jul; 84(7):841-847. PubMed ID: 38833193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent developments in the management of resistant hypertension: focus on endothelin receptor antagonists.
    Heidari Nejad S; Azzam O; Schlaich MP
    Future Cardiol; 2024; 20(9):435-445. PubMed ID: 38953510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Endothelin Antagonism with Aprocitentan as a Novel Therapeutic Approach for Resistant Hypertension.
    Heidari Nejad S; Azzam O; Schlaich MP
    Curr Hypertens Rep; 2023 Oct; 25(10):343-352. PubMed ID: 37566184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aprocitentan and the endothelin system in resistant hypertension.
    Clozel M
    Can J Physiol Pharmacol; 2022 Jul; 100(7):573-583. PubMed ID: 35245103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension.
    Trensz F; Bortolamiol C; Kramberg M; Wanner D; Hadana H; Rey M; Strasser DS; Delahaye S; Hess P; Vezzali E; Mentzel U; Ménard J; Clozel M; Iglarz M
    J Pharmacol Exp Ther; 2019 Mar; 368(3):462-473. PubMed ID: 30622171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension.
    Angeli F; Verdecchia P; Reboldi G
    Cardiol Ther; 2021 Dec; 10(2):397-406. PubMed ID: 34251649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aprocitentan, a dual endothelin-1 (ET-1) antagonist for treating resistant hypertension: Mechanism of action and therapeutic potential.
    Xu J; Jiang X; Xu S
    Drug Discov Today; 2023 Nov; 28(11):103788. PubMed ID: 37742911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension: A Systematic Review and Meta-Analysis.
    Mahfooz K; Najeed S; Tun HN; Khamosh M; Grewal D; Hussain A; Ong K; Dharmarajan L; Vasavada A
    Curr Probl Cardiol; 2023 Jul; 48(7):101686. PubMed ID: 36893968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aprocitentan (a Dual Endothelin-Receptor Antagonist) for Treatment-Resistant Hypertension.
    McCoy EK; Lisenby KM
    J Cardiovasc Pharmacol; 2021 Jun; 77(6):699-706. PubMed ID: 34001723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.
    Schlaich MP; Bellet M; Weber MA; Danaietash P; Bakris GL; Flack JM; Dreier RF; Sassi-Sayadi M; Haskell LP; Narkiewicz K; Wang JG;
    Lancet; 2022 Dec; 400(10367):1927-1937. PubMed ID: 36356632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Dual Endothelin Inhibitors in the Management of Resistant Hypertension.
    Boutari C; Siskos F
    Life (Basel); 2023 Mar; 13(3):. PubMed ID: 36983961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of novel endothelin antagonists and overview of non-steroidal mineralocorticoid antagonists for treating resistant hypertension: An update.
    Blazek O; Bakris GL
    Eur J Pharmacol; 2024 Sep; 979():176752. PubMed ID: 39047966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension.
    Verweij P; Danaietash P; Flamion B; Ménard J; Bellet M
    Hypertension; 2020 Apr; 75(4):956-965. PubMed ID: 32063059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption, Distribution, Metabolism, and Excretion of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Humans.
    Sidharta PN; Fischer H; Dingemanse J
    Curr Drug Metab; 2021; 22(5):399-410. PubMed ID: 33563190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan.
    Danaietash P; Verweij P; Wang JG; Dresser G; Kantola I; Lawrence MK; Narkiewicz K; Schlaich M; Bellet M;
    J Clin Hypertens (Greenwich); 2022 Jul; 24(7):804-813. PubMed ID: 35686330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelin research and the discovery of macitentan for the treatment of pulmonary arterial hypertension.
    Clozel M
    Am J Physiol Regul Integr Comp Physiol; 2016 Oct; 311(4):R721-R726. PubMed ID: 27534881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension.
    Brussee JM; Sidharta PN; Dingemanse J; Krause A
    J Pharmacokinet Pharmacodyn; 2024 Jun; 51(3):243-252. PubMed ID: 38332190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension.
    Miyagawa K; Emoto N
    Ther Adv Cardiovasc Dis; 2014 Oct; 8(5):202-16. PubMed ID: 24990369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. After 30 years, the first endothelin-receptor antagonist (Aprocitentan) is approved for the treatment of arterial hypertension.
    Tamargo J
    Eur Heart J Cardiovasc Pharmacother; 2024 Aug; 10(5):371-373. PubMed ID: 38754980
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.